Company Overview and News

Lithium Australia stamps its authority as an emerging vertically integrated lithium play

Lithium Australia NL (ASX:LIT) has made substantial ground in the last 12 months in achieving its goal of developing an integrated lithium company.

Argosy Minerals fast tracks Rincon Lithium Project to take advantage of lithium carbonate pricing

Argosy Mineral Limited’s (ASX:AGY) near-term objective is successfully proving a chemical process solution for the production of battery-grade lithium carbonate equivalent (LCE).

Lithium Junior Miner News For The Month Of April 2018

2018-05-01 seekingalpha
Lithium spot and contract price news - Spot prices slightly down, while 2018 contract prices are up.

Lithium Miners News For The Month Of April 2018

2018-04-27 seekingalpha
Lithium spot and contract price news - China spot prices slightly down, global contract prices remain firm.

Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.

Lithium Miners News For The Month Of March 2018

2018-03-26 seekingalpha
Lithium spot and contract price news - Lithium spot prices were stable, while 2018 LCE global contract prices are about 20% higher than 2017.

Time To Buy Some Lithium Miners

2018-03-08 seekingalpha
The lithium miner fundamentals have been improving with several great announcements in the past 3 months, including the move towards electric trucks requiring massive amounts of lithium.

S&P/ASX 200 ends the week on a high, closes up 0.8% on Friday

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) closed only 0.2 points shy of the 6,000 market rounding out its strongest day of trade this week.

S&P/ASX 200 steadily rallies over the morning session to be up 0.6% around midday

The ASX 200 was set to open higher this morning as the ASX 200 futures were trading ~30 points higher than where they were at yesterday’s close.

S&P/ASX 200 has opened up 0.4% this morning, Woolworths misses result

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has opened higher as expected, up 0.4% or 25.8 points to 5,976.7.

S&P/ASX 200 set to open higher, US closes in the black

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) is set to open higher this morning with ASX 200 futures trading ~30 points higher than where they were at yesterday’s close.

S&P/ASX 200 rallies to close up 0.2%, March VIX futures still above 19

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) rallied from its low around 1.00pm to finish up for the day.

S&P/ASX 200 heads south after strong start, down 0.2%, March VIX futures above 19

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has retraced from its morning high to go back into the red.

S&P/ASX 200 opens strongly up 0.3%, Flight Centre and Webjet fly

All of the companies reporting noted below are trading positively except BAL which is down 7.7%.

S&P/ASX 200 set for uncertain open as volatility rears its head again

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) is set for an uncertain open this morning after some volatility in the US over the last two hours of trading.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...